Il Nilotinib nella terapia di prima linea della leucemia mieloide cronica
Background: Nilotinib is a potent and selective BCR-ABL inhibitor. The phase 3 ENESTnd trial demonstrated superior efficacy nilotinib vs imatinib, with higher and faster molecular responses. After 24 months, the rates of progression to accelerated-blastic phase (ABP) were 0.7% and 1.1% with nilotin...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Doctoral Thesis |
| Language: | it |
| Published: |
Alma Mater Studiorum - Università di Bologna
2011
|
| Subjects: | |
| Online Access: | http://amsdottorato.unibo.it/3718/ |